ResMed Future Growth
Future criteria checks 2/6
ResMed is forecast to grow earnings and revenue by 11.1% and 7.1% per annum respectively. EPS is expected to grow by 11.1% per annum. Return on equity is forecast to be 22% in 3 years.
Key information
11.1%
Earnings growth rate
11.1%
EPS growth rate
| Medical Equipment earnings growth | 17.1% |
| Revenue growth rate | 7.1% |
| Future return on equity | 22.0% |
| Analyst coverage | Good |
| Last updated | 04 Nov 2024 |
Recent future growth updates
Recent updates
Shareholders May Not Be So Generous With ResMed Inc.'s (NYSE:RMD) CEO Compensation And Here's Why
Nov 13
We Think ResMed (NYSE:RMD) Can Manage Its Debt With Ease
Nov 01Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today
Oct 20ResMed Inc.'s (NYSE:RMD) Intrinsic Value Is Potentially 47% Above Its Share Price
Oct 08Why ResMed's Rally Is Just Getting Started
Sep 18ResMed Inc.'s (NYSE:RMD) Earnings Haven't Escaped The Attention Of Investors
Sep 13ResMed (NYSE:RMD) Is Increasing Its Dividend To $0.53
Aug 05Does ResMed (NYSE:RMD) Have A Healthy Balance Sheet?
Jul 29Returns On Capital Are A Standout For ResMed (NYSE:RMD)
Jul 15ResMed: Asymmetrical Value Opportunity With High Prospect Of Re-Rating
Jul 03An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 33% Undervalued
Jul 02ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly
Apr 30Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Apr 30ResMed Inc.'s (NYSE:RMD) Popularity With Investors Is Clear
Apr 18With EPS Growth And More, ResMed (NYSE:RMD) Makes An Interesting Case
Mar 22Capital Investments At ResMed (NYSE:RMD) Point To A Promising Future
Mar 10An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 30% Undervalued
Feb 12Why ResMed Is One Of My Top Picks In 2024
Jan 22A First Look At ResMed
Jan 09ResMed Inc.'s (NYSE:RMD) Share Price Could Signal Some Risk
Dec 20Why You Should Care About ResMed's (NYSE:RMD) Strong Returns On Capital
Dec 06Shareholders May Find It Hard To Justify Increasing ResMed Inc.'s (NYSE:RMD) CEO Compensation For Now
Nov 10Are Investors Undervaluing ResMed Inc. (NYSE:RMD) By 41%?
Nov 01ResMed: Weight-Loss Drug Worries Provide Buying Opportunity
Oct 28ResMed: Stock Re-Rating To 20x Forward P/E Is A Buy Opportunity
Sep 12ResMed Has Become A Steal (Rating Upgrade)
Aug 10ResMed's (NYSE:RMD) Shareholders Will Receive A Bigger Dividend Than Last Year
Aug 07ResMed (NYSE:RMD) Has Some Way To Go To Become A Multi-Bagger
Jul 30Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today
Jul 16Compound Your Wealth With ResMed
Jul 04A Look At The Fair Value Of ResMed Inc. (NYSE:RMD)
Jul 02We Think ResMed (NYSE:RMD) Can Stay On Top Of Its Debt
May 26Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 6/30/2027 | 5,890 | 1,609 | 1,602 | 1,724 | 18 |
| 6/30/2026 | 5,494 | 1,471 | 1,501 | 1,595 | 21 |
| 6/30/2025 | 5,124 | 1,328 | 1,267 | 1,388 | 22 |
| 9/30/2024 | 4,807 | 1,113 | 1,347 | 1,441 | N/A |
| 6/30/2024 | 4,685 | 1,021 | 1,286 | 1,401 | N/A |
| 3/31/2024 | 4,584 | 958 | 1,071 | 1,199 | N/A |
| 12/31/2023 | 4,504 | 890 | 944 | 1,079 | N/A |
| 9/30/2023 | 4,375 | 907 | 792 | 935 | N/A |
| 6/30/2023 | 4,223 | 898 | 559 | 693 | N/A |
| 3/31/2023 | 4,016 | 863 | 408 | 535 | N/A |
| 12/31/2022 | 3,763 | 809 | 222 | 370 | N/A |
| 9/30/2022 | 3,624 | 786 | 305 | 461 | N/A |
| 6/30/2022 | 3,578 | 779 | 195 | 351 | N/A |
| 3/31/2022 | 3,539 | 779 | 344 | 498 | N/A |
| 12/31/2021 | 3,444 | 522 | 446 | 577 | N/A |
| 9/30/2021 | 3,349 | 500 | 397 | 527 | N/A |
| 6/30/2021 | 3,197 | 475 | 620 | 737 | N/A |
| 3/31/2021 | 3,091 | 457 | 733 | 840 | N/A |
| 12/31/2020 | 3,092 | 699 | 774 | 884 | N/A |
| 9/30/2020 | 3,028 | 680 | 684 | 784 | N/A |
| 6/30/2020 | 2,957 | 622 | 696 | 802 | N/A |
| 3/31/2020 | 2,892 | 513 | 505 | 614 | N/A |
| 12/31/2019 | 2,784 | 455 | 420 | 514 | N/A |
| 9/30/2019 | 2,699 | 419 | 487 | 573 | N/A |
| 6/30/2019 | 2,607 | 405 | 382 | 459 | N/A |
| 3/31/2019 | 2,525 | 446 | 374 | 447 | N/A |
| 12/31/2018 | 2,455 | 450 | 385 | 456 | N/A |
| 9/30/2018 | 2,405 | 335 | 390 | 459 | N/A |
| 6/30/2018 | 2,340 | 316 | N/A | 505 | N/A |
| 3/31/2018 | 2,273 | 307 | N/A | 516 | N/A |
| 12/31/2017 | 2,196 | 285 | N/A | 434 | N/A |
| 9/30/2017 | 2,125 | 352 | N/A | 422 | N/A |
| 6/30/2017 | 2,067 | 342 | N/A | 414 | N/A |
| 3/31/2017 | 2,029 | 324 | N/A | 417 | N/A |
| 12/31/2016 | 1,968 | 327 | N/A | 474 | N/A |
| 9/30/2016 | 1,893 | 346 | N/A | 510 | N/A |
| 6/30/2016 | 1,839 | 352 | N/A | 548 | N/A |
| 3/31/2016 | 1,773 | 357 | N/A | 505 | N/A |
| 12/31/2015 | 1,742 | 357 | N/A | 471 | N/A |
| 9/30/2015 | 1,710 | 353 | N/A | 421 | N/A |
| 6/30/2015 | 1,679 | 353 | N/A | 383 | N/A |
| 3/31/2015 | 1,641 | 353 | N/A | 399 | N/A |
| 12/31/2014 | 1,616 | 352 | N/A | 409 | N/A |
| 9/30/2014 | 1,578 | 348 | N/A | 387 | N/A |
| 6/30/2014 | 1,555 | 345 | N/A | 391 | N/A |
| 3/31/2014 | 1,554 | 331 | N/A | 400 | N/A |
| 12/31/2013 | 1,540 | 325 | N/A | 406 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RMD's forecast earnings growth (11.1% per year) is above the savings rate (2.6%).
Earnings vs Market: RMD's earnings (11.1% per year) are forecast to grow slower than the US market (15.3% per year).
High Growth Earnings: RMD's earnings are forecast to grow, but not significantly.
Revenue vs Market: RMD's revenue (7.1% per year) is forecast to grow slower than the US market (8.9% per year).
High Growth Revenue: RMD's revenue (7.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: RMD's Return on Equity is forecast to be high in 3 years time (22%)